Inventor
MAHLERT CHRISTOPH
DE16 patents
⚠️ This page may combine multiple inventors who share the name “MAHLERT CHRISTOPH”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
Bayer Pharma AG
13 patentsUS10973923B2Apr 13, 2021
Site specific homogeneous with KSP inhibitors
Bayer Pharma AG8 citations83
US10744205B2Aug 18, 2020
Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies
Bayer Pharma AG9 citations83
US10485880B2Nov 26, 2019
Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies
Bayer Pharma AG11 citations83
US10022453B2Jul 17, 2018
Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
Bayer Pharma AG16 citations83
US11478554B2Oct 25, 2022
Antibody drug conjugates (ADCS) having enzymatically cleavable groups
Bayer Pharma AG5 citations82
US11123439B2Sep 21, 2021
Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups
Bayer Pharma AG8 citations82
US11660351B2May 30, 2023
Antibody drug conjugates (ADCs) having enzymatically cleavable groups
Bayer Pharma AG5 citations73
US11001636B2May 11, 2021
Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
Bayer Pharma AG5 citations72
US11685714B2Jun 27, 2023
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
Bayer Pharma AG3 citations71
US11071788B2Jul 27, 2021
Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
Bayer Pharma AG6 citations70
US11806404B2Nov 7, 2023
Site specific homogeneous with KSP inhibitors
Bayer Pharma AG0 citations62
US12144865B2Nov 19, 2024
Antibody drug conjugates with enzymatically cleavable groups
Bayer Pharma AG0 citations61
US11643469B2May 9, 2023
Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies
Bayer Pharma AG1 citations61